About 15 employees are affected, about 28% of its workforce, according to BioXcel Therapeutics, Inc.'s latest layoff filing, on September 19, 2024. As of November 14, 2026, BioXcel Therapeutics, Inc. has reported this one exit or restructuring plan to the SEC on Form 8-K under Item 2.05. No WARN notice under its name is on file in the states covered here (Form 8-K, September 19, 2024).
10 companies announced layoffs this week, 1 had other signals.
Companies cutting jobs this week. Before you unlock: the company, the number of employees and what is inside. After: every way we found to reach the company. No individual is named in a layoff.
| UPWORK, INC | announced layoffs | |
| PVH CORP. /DE/ | announced layoffs | |
| Battelle | filed a layoff notice for 15 employees | |
| TidalHealth Primary Care | filed a layoff notice for 5 employees | |
| Phunware, Inc. | announced layoffs |
Is this your company?
Owed money by them or selling to them? See the free Snapshot of BioXcel Therapeutics, Inc.
Free to see. No signup.
People from BioXcel Therapeutics, Inc. who say they are open to work
Only people who added themselves are listed here. Nobody is named because of a company announcement or a news story, and we have not checked what anyone says about themselves.
Loading the list…
Affected by the BioXcel Therapeutics, Inc. layoff? Add yourself to the open-to-work list, free
Your entry
BioXcel Therapeutics, Inc. reported 1 exit or restructuring plan on Form 8-K under Item 2.05, 1 of 1 stating how many employees or positions are affected. Each fact below is the filing's own sentence, quoted and linked. No WARN notice under this company's name is on file in the states covered here.
Did BioXcel Therapeutics have layoffs in 2024? What its filings say
BioXcel Therapeutics, Inc. (CIK 1720893) reported 1 exit or restructuring plan to the SEC on Form 8-K under Item 2.05. The sentences below are quoted from the filings as written.
Form 8-K filed 2024-09-19
Employees affected
On September 17, 2024, the Board of Directors (the "Board") of BioXcel Therapeutics, Inc. (the "Company") approved a plan to reduce its workforce by 15 employees, or approximately 28% of the Company's headcount (the "Clinical Prioritization"), in order to extend its cash runway and prioritize investment on the clinical development of its lead neuroscience asset, BXCL501.
Expected charges
The Company estimates that it will incur aggregate charges in connection with the Clinical Prioritization of approximately $1.4 million, which relate primarily to severance payments, notice pay and related continuation of benefits costs, all of which are expected to be paid in cash and anticipated to result in future cash expenditures, along with the payment of accrued benefits (such as paid-time-off).
Timing
The Company expects that the majority of these costs will be incurred, and the Clinical Prioritization is expected to be completed, during the quarter ending December 31, 2024.
Also on the record for BioXcel Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 30, 2026 | Leadership change: Samir Saleem appointed, President, and 1 more | — | Leadership changes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 4.99% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Armistice Capital, LLC | 7.05% of the class | 5%+ stakes | Source |
| March 30, 2026 | Stake report, Schedule 13G/A, by Qatar Investment Authority | 0.6% of the class | 5%+ stakes | Source |
| February 9, 2026 | Stake report, Schedule 13G/A, by Integrated Core Strategies (US) LLC | 8.4% of the class | 5%+ stakes | Source |
| October 1, 2025 | Stake report, Schedule 13G, by Integrated Core Strategies (US) LLC | 5.2% of the class | 5%+ stakes | Source |
Keep reading
More on BioXcel Therapeutics, Inc. and the records around it.
BioXcel Therapeutics, Inc. elsewhere on the record
- Leadership changes Oct 2026
- 5%+ stake filings Aug 2026
- Bankruptcy record
- Who owns it
Companies that share a holder
- Qatar Investment Authority also filed stake reports on 12 other companies: Autolus Therapeutics PLC (Nov 2026), Aspen Neuroscience, Inc. (Nov 2026), Global Business Travel Group, Inc. (Sep 2026)
- Integrated Core Strategies (US) LLC also filed stake reports on 63 other companies: Surrozen, Inc. (Nov 2026), Lyft, Inc. (Nov 2026), Once Upon a Farm, PBC (Nov 2026)
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), Bluejay Diagnostics (Aug 2026)
Watch BioXcel Therapeutics, Inc.
Get an email when BioXcel Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
What do you want to do with BioXcel Therapeutics, Inc.?
Want the whole picture on BioXcel Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on BioXcel Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on BioXcel Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Tools for this story
Each opens in a new tab, filled in for BioXcel Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Public companies must also report to the SEC, on Form 8-K under Item 2.05, when they commit to an exit or restructuring plan that will cost them material charges, which is how most large layoffs and closures by listed companies are disclosed. Those filings are national, so they cover companies in every state. Each sentence shown from one is quoted exactly and linked to the filing; where a filing does not state a figure, none is shown.
Where this comes from
Employers covered by the federal WARN Act, and by the stricter laws some states add, must give written notice before a mass layoff or a site closure. The state labor department publishes those notices. Every row here is one of them, taken from that state's own published file and linked to it, so each figure can be checked at the source.
A notice states the employer, the location, the number of employees affected, and when the layoff or closure takes effect. It does not state a reason, and neither does this page. Where a company also appears in SEC filings under the same name and in the same state, its recorded fundraising is shown alongside, as a matter of record rather than as an explanation. New Jersey and Pennsylvania list a notice under the month it was posted or received, not the day, so their notices show a month. Tennessee gives the county rather than the city.
Who owns BioXcel Therapeutics, Inc.? Owners, funding and legal record
Cite this page
https://mentionfox.com/layoffs/bioxcel-therapeutics